RxDoctor Payments Data

Mitchell Maier

Optometrist · Spokane, WANPI 1306844154

Payments from drug & device makers

$1,273in general payments, 2019–2025

Across 29 payments — averaging $43.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$333
  • Alcon$304
  • AbbVie$156
  • Johnson & Johnson Surgical Vision, Inc.$140
  • Astellas Pharma US Inc$125
  • Bausch & Lomb Americas Inc.$114
  • plus $102 from 3 others

What the payments were for

  • Food & beverage$94074%
  • Ownership interest$33326%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,273 in reported general payments places this provider in the 70th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$204,163
Medicare patients
1,161
Services billed
2,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$90,025
Cyclosporine40$26,605
XiidraLifitegrast13$23,396
LumiganBimatoprost14$8,827
Latanoprost553$7,896
Doxycycline Hyclate15$1,691
Timolol Maleate191$1,478
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat87$1,384
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha97$1,163
Brimonidine Tartrate28$1,149
Prednisolone Acetate32$1,055
ErythromycinErythromycin Base56$671
Dorzolamide Hcl11$429
Ofloxacin15$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$156$98,85295 claims
Bausch & Lomb Americas Inc.Xiidra$114$23,39613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →